Leerink raised the firm’s price target on BrightSpring Health to $17 from $15 and keeps an Outperform rating on the shares. The firm notes Q1 results brought forth exceptional top-line growth, broad-based outperformance vs. plan, and very strong volume execution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services, Inc. Welcomes Timothy A. Wicks to Board of Directors
- BrightSpring Health Appoints New Independent Director Wicks
- BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®
- BrightSpring Health Services, Inc. to Announce First Quarter 2024 Financial Results on May 2, 2024, and Participate in the Bank of America 2024 Healthcare Conference
- BrightSpring Health Services Applauds Hundreds of Award-Winning Employees for their Recognition of Outstanding Service and Care